Industry Trends
Largest Transactions Closed
- Target
- Buyer
- Value($mm)
Advised Western Milling in their sale to the Western Milling ESOP Trust
Last updated:
Executive Summary
Healthcare M&A remained strategically resilient through Q3 2026 despite a meaningful decline in deal volume. Valuations strengthened to median multiples of 14.25x TEV/EBITDA and 3.77x TEV/Revenue, while strategic buyers drove 838 transactions, or 89.2% of LTM activity. Overall, 939 transactions closed during the last twelve months, down 16.0% from 1,118 in the prior-year period; financial buyers completed 101 deals. Healthcare also represented 7.2% of Q3 transaction volume, compared with 6.9% on an LTM basis, signaling sustained buyer demand in a more selective market.1
“Operational strength is becoming the key differentiator for healthcare businesses as buyers weigh rising labor costs, reimbursement pressure, and affordability concerns,” said Bradley Scharfenberg, Vice President at PCE. “Companies with efficient staffing, durable margins, and a clear value proposition for patients and providers will be best positioned to stand out.”
Market Dynamics
Q3 accounted for 162 healthcare transactions, representing approximately 17% of the 939 healthcare deals completed during the LTM period. Quarterly activity therefore remained below the average for the trailing twelve months, pointing to continued near-term softness rather than a broad-based rebound in transaction volume.
Buyer Landscape
Strategic Acquirers: Strategic buyers dominated Q3 2026 activity, representing 838 deals (89.2%) in the LTM period. The largest announced outcomes reflected continued demand for therapeutics and specialty healthcare assets, led by AbbVie’s $10.7B acquisition of Apogee Therapeutics, GlaxoSmithKline’s $10.6B acquisition of Nuvalent, and Vertex Pharmaceuticals’ $8.9B acquisition of Crinetics Pharmaceuticals.1
Financial Buyers: Financial sponsors accounted for 101 deals (10.8%) in the LTM period. Representative Q3 2026 transactions included Montagu Private Equity and Kohlberg & Company’s $1.5B acquisition of Telex Medical OEM, AIP’s $1.3B acquisition of Arams Medical, and Astorg’s $1.1B acquisition of Thermo Fisher Scientific’s global microbiology business.1
Industry Comparison
Healthcare transaction activity remained comparatively resilient within the broader M&A market. The sector represented 7.2% of all Q3 2026 transactions, above its 6.9% share of LTM volume, indicating that healthcare captured a modestly larger portion of deal activity during the quarter despite lower absolute transaction volume. The increase in relative share suggests sector demand held up better than the headline volume decline across industries.
Geographic Expansion
Top U.S. States: Deal flow remained geographically diversified across major healthcare and life sciences hubs. California led all states with 138 transactions, followed by Florida (88), Texas (70), Massachusetts (53), and New York (52).1
Cross-Border Trends: Cross-border M&A activity in Q3 2025 was driven by major European acquirers such as Sanofi, Merck KGaA, and GSK, which pursued U.S. biotech and therapeutic assets to expand global pipelines and strengthen specialty drug portfolios.
Notable Transactions
Largest Transactions Closed
| Target | Buyer | Value ($mm) |
| Apogee Therapeutics, Inc. | AbbVie Inc. | $10,695 |
| Nuvalent, Inc. | GlaxoSmithKline LLC | $10,629 |
| Crinetics Pharmaceuticals, Inc. | Vertex Pharmaceuticals Incorporated | $8,866 |
| Catalyst Pharmaceuticals, Inc. | Angelini Pharma S.p.a. | $4,100 |
| AtaiBeckley Inc. | Eli Lilly and Company | $3,722 |
| Sevasemten and Muscular Dystrophy Business of Edgewise Therapeutics, Inc | Servier Pharmaceuticals LLC | $2,650 |
| Forte Biosciences, Inc. | argenx SE | $2,118 |
| Vega Therapeutics, Inc. | Incyte Corporation | $2,000 |
| Kartos Therapeutics, Inc. | Ipsen S.A. | $1,750 |
| Esperion Therapeutics, Inc. | ArchiMed SAS | $1,543 |
Other Financial Buyer Transactions Closed
| Target | Buyer | Value ($mm) |
| Teleflex Medical OEM LLC | Montagu Private Equity LLP; Kohlberg & Company, L.L.C. | $1,500 |
| Avanos Medical, Inc. | AIP, LLC | $1,397 |
| Global Microbiology Business of Thermo Fisher Scientific Inc. | Astorg Asset Management S A.R.L. | $1,075 |
| MatrixCare, Inc. | Frazier Management, L.L.C. | $490 |
| Cross Country Healthcare, Inc. | Knox Lane LP | $439 |
Other Strategic Buyer Transactions Closed
| Target | Buyer | Value ($mm) |
| Riverpoint Medical, LLC | Novanta Inc. | $1,450 |
| Actio Biosciences, Inc. | Jazz Pharmaceuticals plc | $1,320 |
| Kashiv BioSciences, LLC | Amneal Pharmaceuticals, Inc. | $1,102 |
| XOMA Royalty Corporation | Ligand Pharmaceuticals Incorporated | $1,049 |
| RayThera Inc. | Biogen Inc. | $1,000 |
Source S&P Capital IQ as of 10/1/2026 and PCE Proprietary Data
Emerging Trends
Key trends shaping Healthcare M&A:
- AI Moves from Pilot to Productivity:
Healthcare buyers are prioritizing platforms with measurable workflow benefits: 36% of surveyed clinicians said AI increased weekly patient capacity, while 30% reported budget savings; however, 77% cited limited or inconsistent training, elevating implementation readiness in diligence.2 - Affordability Pressure Reshapes Provider Strategy:
Private-insurance hospital prices rose 30% from April 2019 to April 2026 versus 21% for Medicare, intensifying pressure on health systems to demonstrate cost control, differentiated outcomes, and scalable outpatient delivery.3 - Outpatient Technology Gains Momentum:
Surgical robotics competition expanded as Medtronic, Stryker, CMR Surgical, and Distalmotion advanced new platforms, with ambulatory surgery centers emerging as a key adoption channel.4 - Labor Economics Remain Central:
Private-sector employee compensation costs increased 3.4% year over year through June 2026, including 3.2% wage growth and 3.8% benefit-cost growth, reinforcing buyer focus on staffing efficiency and margin durability.5 - Subsector Spotlight: Hospitals / Integrated Delivery Systems
Rising commercial prices and affordability scrutiny are pushing systems toward outpatient capacity, tighter care coordination, and technology-enabled productivity. Platforms that can document lower costs and better outcomes should be best positioned.3 - Subsector Spotlight: Medical Devices & Technology (MedTech)
Robotics is broadening across soft-tissue, orthopedic, cardiac, and other specialties, while smaller and more flexible systems target ambulatory settings where space, capital cost, and workflow integration remain key adoption barriers.4
Outlook for Next Quarter
Opportunities: Q4 2026 interest should favor AI-enabled workflow tools, scalable outpatient models, and medtech platforms that expand procedural capacity while demonstrating clear clinical and financial ROI.2 4
Risks: Wage and benefit inflation, reimbursement pressure, implementation costs, and heightened scrutiny of provider pricing may temper valuations for labor-intensive or operationally complex assets3 5
Predicted Activity: Activity should remain selective but steady, led by strategic tuck-ins and sponsor-backed platforms with defensible specialties, recurring revenue, and credible technology-enabled margin expansion.
PCE Transactions
Contact Us
David Jasmund |
Jon Gogolak |
Bradley Scharfenberg |
